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Oral squamous cell carcinoma has a remarkable incidence worldwide and a fairly onerous prognosis, encouraging
further research on factors that might modify disease outcome. In this review article, the authors approach the factors that
may exert influence on the prognosis and eventually guide the selection of patients for more aggressive therapies. Published
scientific data was collected, selected, and grouped into 3 main clusters: patient-, tumor-, and treatment-related factors. Well
established aspects are discussed, but also those less common or with only supposed usefulness. Disease staging, extracapsular
dissemination, resection margin free of disease, and tumor thickness are factors with high influence on the prognosis. There has
been an increasing interest in the study of tumor molecular factors, and some have been strongly correlated with the outcome,
showing promising pathways for the future development of more effective prognosis systems and anticancer therapies.
(Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:67-76)Squamous cell carcinomas (SCC, Fig. 1) encompass
at least 90% of all oral malignancies.1,2 Oral cancer
holds the eighth position in the cancer incidence ranking
worldwide, with epidemiologic variations between dif-
ferent geographic regions (it is the third most common
malignancy in south-central Asia).3 The World Health
Organization expects a worldwide rising oral squamous
cell carcinomas (OSCC) incidence in the next decades.
In the US, OSCC represents 2%-4% of the annually di-
agnosed malignancies, being responsible for 8,000
deaths every year.4,5 In the US, at the time of diagnosis,
36% of patients have localized disease, 43% regionally
spread disease, and 9% present distant metastasis.4 In
some western European countries, such as Belgium,
Denmark, Greece, Portugal, and Scotland, there has
been an upward trend in the incidence of OSCC. Increas-
ing mortality rates have been observed for at least 2 de-
cades in Eastern Europe, where OSCC comprises a real
public health issue.6 OSCC implies quite significant
mortality and morbidity rates,1,2,4,5 and in spite of the
vast amount of research and the advances accomplished
in the field of oncology and surgery, the mortality rates
remain unchanged. This motivates the search of factors
with prognostic relevance in order to better tailor the
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of this article is to list and discuss some of these factors,
focusing also on some of the most promising.
METHODS
A web-based search for all types of articles published
was initiated using MEDLINE/PubMed, with the key
words ‘‘oral,’’ ‘‘cancer,’’ and ‘‘prognosis.’’ The search
was subsequently refined. The sites of specialized scien-
tific journals in the areas of oral and maxillofacial
surgery, oral medicine, and oncology were also used.
In order to achieve a concise and informative text all
authors were engaged in the selection of the informa-
tion to be used, first on an individual basis and the
final choice accomplished by group consensus. We have
subsequently devised a wide-ranging selection of factors
with potential influence on the outcome of this disease,
whether well established ones or more recent with only
conjectural usefulness. No additional statistical analysis
has been conducted. Three clusters of issues were for-
mulated: patient-, tumor-, and treatment-related factors.
REVIEW OF THE LITERATURE
Patient-related factors
Sex and age. Apparently, there are no prognostic dif-
ferences between males and females,7-9 although some
authors have reported lower survival rates in females,
attributed to delay in seeking medical care and lower
acceptance of treatment.10 The correlation of prognosis
with age seems controversial, and some authors show no
relationship between them,7-9,11 whereas others demon-
strate worse prognosis in older patients.10,12
Tobacco and alcohol. Although some results deny
any association between survival and smoked tobacco
or alcohol consumption,7 most authors report higher
mortality in smokers and alcohol drinkers.10,12,13 Betel67
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and some Asian communities in the western world) has
been specifically correlated with poorer prognosis.7
Smokers and alcohol drinkers seem to be at higher
risk for the development of second primary oral cancer
than nonsmokers and nondrinkers, thus facing more
onerous outcomes.14-17 This is also the case for those
who maintain tobacco and alcohol consumption fol-
lowing diagnosis of the primary tumor.15-18 Clinicians
should therefore make every effort to persuade all
patients (including those already treated for OSCC) to
abandon these detrimental habits.
Socioeconomic conditions. Apparently, the outcome
issomewhatworseforpatientswithlowersocioeconomic
status and education, most likely because of poorer oral
hygiene and more difficult access to medical care.10
Diagnostic delays. It seems highly likely that di-
agnostic delays raise the probability of higher tumor
growth and spread, consequently aggravating the prog-
nosis. However, an extensive review concerning OSCC
pointed out that the available data fail to demonstrate
this thesis,19 a fact partially attributed to methodologic
insufficiencies of the published studies. Another pos-
sible theory is that patients with more hostile tumors
develop symptoms earlier, seeking medical attention
sooner; nevertheless, these patients still have to face a
more grievous outcome, because these malignancies
display a more aggressive biologic behavior.
Miscellaneous. Comorbid conditions may worsen
disease outcome as a consequence of increased organic
stress afflicting the patient.12,13,20 Survival rates are
lower in patients with concomitant OSCC and disorders
such as congestive heart failure, arrhythmias, peripheral
vascular disease, pulmonary and renal diseases, and
other cancers, either treated or untreated.20 Depressed
host immune status seems to play an adverse role on sur-
vival of patients with oral cancer. Patients under immu-
nosuppressive therapy following solid organ transplant
Fig. 1. Squamous cell carcinoma of the retromolar trigone,
presenting as an ulcerated lesion (photograph taken with the
patient’s consent).who developed OSCC fare worse than individuals
with a less depressed immune system.21 Additionally,
there is an association between lower 5-year survival
rates in patients with OSCC and evidence of immune
depression.22 These facts highlight the importance of
immune response in tumor control and the potential
value of cancer immunotherapy.22,23 Some specific
symptoms, such as odynophagia, oral abnormal hemor-
rhage, and weight loss, also have been correlated with
shorter survival.12 Weight loss is associated with higher
mortality rates in patients with OSCC with recurrence or
persistence of disease, or second primary tumor.9
Tumor-related factors
Anatomic site. Vascular and lymphatic networks,
which vary between different anatomic sites, may in-
fluence tumor evolution and the outcome. Higher
metastatic disease rates for SCC at the base rather
than at the oral tongue have been reported.24 Leite and
Koifman10 showed higher mortality rates in patients
with tongue carcinomas than in those who developed
lip carcinomas. In addition, some anatomic sites are
linked with poorer outcome owing to the rich lym-
phatic drainage and the local extension being hard to
evaluate and manage, such as the superior gingivolabial
sulcus.25
Disease staging. Cancer staging is based on the TNM
system, which has been labeled as imperfect, per se, for
prognostic purposes.8,9,12,13,26-30 However, the vast ma-
jority of authors accepts that disease staging has a cru-
cial influence on the outcome. Guerra et al.31 reported
5-year survival rates of 82% for initial stages and 49%
for advanced disease. Lo et al.7 described 5-year survival
rates of 75%, 65.6%, 49%, and 30% for disease stages
I, II, III, and IV, respectively. Gonzales-Moles et al.26
Fig. 2. Exuberant late cervical metastases from previously
treated squamous cell carcinoma of the inferior lip (photo-
graph taken with the patient’s consent).
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logic T, N, and pathologic N on the vital prognosis.
Nguyen and Yueh9 found 1-year survival rates of 60%
(stage I) and 32% (stage IV) in patients with recurrence,
persistent disease, or second primary cancer.
Cervical node metastases (Fig. 2) have variable
incidence and are widely accepted as one of the major
prognostic factors in patients with OSCC.32-35 Their
presence is associated with a decrease in global survival
to roughly half as well as with higher recurrence
rates.24,34-36 Cervical node metastases may be classified
into 2 distinct categories: overt (clinical) or nonovert
(occult). The latter may be further categorized as meta-
static deposits detectable by traditional methods (stain-
ing with hematoxylin and eosin and observed with light
microscopy) or ‘‘submicroscopic’’ metastases, only ap-
parent after performing immunohistochemical or mo-
lecular analysis of the dissected lymph nodes.32 These
techniques seem quite promising, given that in patients
with no clinical or radiologic evidence of metastatic
dissemination, occult node metastases were detected
in 20%-40% of cases.36 A retrospective study involving
266 patients who had previously undergone surgery and
cervical node dissection, revealed that 34% of those ini-
tially classified as cN0 had, in fact, occult metastatic dis-
ease (pN1).33 Therefore, staging based on pathologic
analysis following neck dissection should be consid-
ered, in order to identify high-risk patients who may
benefit from adjuvant therapy, because those with
node metastases show significantly lower survival rates
than those with disease-free nodes.33,34
Tumor thickness. The risk of nodal metastases and
mortality rates vary directly with the thickness of the
primary tumor.8,11,26 O-charoenrat et al. found that
tumor thickness above 5 mm is a strong predictor of
occult nodal metastases and should indicate an elective
neck dissection.8 There is evidence that tumor thickness
may exercise more influence on the survival rates than
factors such as clinical and pathologic staging.26
Extracapsular spread (ECS). Defined as extranodal
extension of metastatic deposits outside the lymph
node capsule (Fig. 3), ECS is a noticeably important
prognostic factor, associated with higher locoregional
recurrence rates, distant metastases, and lower survival
rates.33,35,36 Some authors report a decrease in survival
rates between 29% and 60%, as well as an increase in
nodal metastases rates, when ECS is observed34; others
show 5-year survival rates of 21% in patients with ECS
vs 64% for those with intranodal metastases.35 A de-
scriptive evaluation system of ECS extension subdivides
it into macro- and microscopic.36 Macroscopic ECS is
evident to the naked eye, and microscopic ECS is only
demonstrable during histologic analysis. By studying
the cervical nodes of 173 patients diagnosed withOSCC and histologically confirmed presence of nodal
metastases, Woolgar et al.35 found that the 3-year sur-
vival probability was similar in those with macroscopic
or microscopic ECS (33% and 36%, respectively) and
much worse than the rate of 72% for those with strict
intranodal metastases. Additionally, it has been found
that patients with multiple metastatic nodes have poorer
prognosis, and individuals with multiple nodes with
ECS show an extremely short median time interval until
disease recurrence as well as higher mortality rates.36
These findings support the notion that these patients
Fig. 3. A, Lymph node metastasis from well differentiated
OSCC. There is lymph node capsule thinning and invasion
(although not complete destruction). Asterisk marks perinodal
fat tissue. H&E, original magnification350 (courtesy of Pro-
fessor Silve´rio Cabrita, Department of Experimental Pathol-
ogy, Faculty of Medicine, University of Coimbra, Portugal).
B, Microscopic extracapsular spread, not detectable by mac-
roscopic examination. Lymph node metastasis from well dif-
ferentiated OSCC (thick arrows), with necrotic area shown
(triangle). A cluster of cancer cells is shown (thin horizontal
arrow), and what seem to be remnants of the lymph node cap-
sule are still visible (thin oblique arrow). Asterisk marks peri-
nodal fat tissue. H&E, original magnification 3100 (courtesy
of Dr. Maria Jose´ Julia˜o, Department of Pathology, Coimbra
University Hospital, Portugal).
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didates for adjuvant treatment intensification. In a series
of 266 patients treated surgically, with or without adju-
vant radiotherapy, Greenberg et al.36 established the
5-year disease-specific survival rates of 88% for those
classified as pN0, 65% for patients pN1/ECS, and
48% for those pN1/ECS1. Therefore, it seems impor-
tant to integrate ECS into pathologic staging systems,
including microscopic ECS.35 The additional costs
would probably be low compared to the final benefits.
Histologic differentiation. Most authors have estab-
lished significant correlations between lower histologic
differentiation and poorer prognosis,7,9,20,27,37 but
others did not find such association.8,10,11
Perineural invasion. Perineural invasion apparently
correlates with higher probability of regional and distant
metastases, higher depth of tumor invasion, lower differ-
entiation, and lower 5-year survival rates in OSCC.38
Rodolico et al.39 showed that perineural invasion corre-
lates with the risk of nodal metastases.
Angiogenesis. Malignancies have the ability to in-
duce growth of new blood vessels, which is important
for tumor progression, aggressiveness, and ability to
metastasize. It is a highly regulated and complex pro-
cess.40 Most authors assess tumor angiogenesis by
counting the number of blood vessels (microvessel den-
sity, MVD) in tissue sections. Vessels are observed using
several immunohistochemical staining techniques.41,42
Other methods have been developed to evaluate angio-
genesis, such as the Chalkley method and flow cytome-
try vessel counting.41,42 Using the MVD technique,
Shpitzer et al.28 have studied early-stage tongue SCC
angiogenesis, reporting that it may be an important fac-
tor for tumor hostility. Marked angiogenesis correlated
well with the risk of nodal metastases and should prob-
ably imply a more aggressive postoperative adjuvant
therapy. Moreover, OSCC angiogenesis correlates with
T and N parameters and is an independent predictor of
tumor recurrence and a reliable prognosticator.29
The VEGF plays a decisive role in the development of
blood vessels; it is a key component in tumor angiogen-
esis, and 4 subtypes have been described (A, B, C, and
D).43,44 Shintani et al.43 recently described its expres-
sion in OSCC, correlating subtypes A and B with tumor
angiogenesis and subtypes C and D with the risk of
nodal metastases. The latter were also frequently up-
regulated in the invasive front of the tumor, indicating
a possible role in the process of tumor invasion and
development of metastases. Uehara et al.44 found a sig-
nificant correlation between the high expression of
VEGF in OSCC and worse prognosis.
Tumor expression of cyclooxygenase-2 (COX-2). Re-
cently, a strong correlation was found in OSCC between
high COX-2 expression and higher lymph nodeinvolvement, higher recurrence rates, and shorter dis-
ease-free survival.45 Marked COX-2 expression was
found in the cytoplasm of cells of the tumor invasive
front and also in the cells of the surrounding stroma
and vessels, indicating a putative role in tumor invasion
and development of metastases.16,46 Another study dem-
onstrated that COX-2 overexpression in OSCC was as-
sociated with higher radioresistance; tumor cells
treated in vitrowith a COX-2 inhibitor showed better re-
sponse to radiotherapy.47 These findings can obviously
have interesting and valuable prognostic and therapeutic
implications.
Molecular markers. Cancer cells result from dis-
ruptions in circuits that regulate proliferation and ho-
meostasis of normal cells.48,49 Although various genetic
changes are associated with several types of disturbances
and many types of cancers, there are 6 typical modifica-
tions in cellular physiology: self-sufficiency of growth
signals, insensitivity to growth-inhibitor signals, evasion
of apoptosis, unlimited replicative potential, ability to
promote sustained angiogenesis, and capacity to invade
surrounding tissues and metastasize.48
Several genetic aberrations have been identified in
OSCC, most frequently in chromosomes 3, 9, 11, 13,
and 17. Among others, the inactivation of tumor-
suppressor genes such as p16 (9p21) and p53 (17p),
the overexpression of oncogenes such as PRAD-1
(11q), and the alteration of genes involved in the metab-
olism of carcinogens or DNA repair seem to play a role
in the carcinogenesis of OSCC.49 Moreover, most oral
carcinomas are telomerase-activity positive.29,50 The
study of these alterations is important for the character-
ization of cancer cells, with implications in the detection
of individual and familial risk, noninvasive early diagno-
sis, tumor staging, therapy, and prognosis.51 Some of the
most thoroughly studied genetic modifications impli-
cated in the prognosis of OSCC are summarized as
follows.
Oncogenes. Epidermal growth factor receptor
(EGFR): EGFR proto-oncogene maps to 7p13-q22, and
encodes a transmembrane protein whose activation by
ligands such as epidermal growth factor or transforming
growth factor alpha triggers a cascade of intracellular bi-
ochemical processes involved in cellular proliferation,
differentiation, migration, and antiapoptotic pathways;
it seems to play a significant role in cancer cell prolifer-
ation, survival, and mobility. Its overexpression is com-
mon in many malignancies, including breast, prostate,
lung, and bladder cancers, correlating with poor progno-
sis.29,49,52,53 In OSCC it has been frequently associated
with advanced T stage, diffuse tumor invasiveness, and
high incidence of cervical node metastases.29 Its expres-
sion has also been correlated with lower histologic tumor
differentiation.54 Recently published works emphasize
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promising results both in vitro and in vivo.55,56 Research
concerning cancer chemoprevention of head and neck
cancer using EGFR tyrosine kinase inhibitors (gefitinib,
erlotinib) is also in progress.52
c-myc: Gene involved in the regulation of genetic ex-
pression and cell cycle. Its overexpression is associated
with loss of differentiation in OSCC, although its corre-
lation with survival is not clear.29
Cyclin D1: Proto-oncogene that regulates cell cycle;
its product, CCND1, phosphorylates Rb, promoting
the transition G1!S. Cyclin D1 activity is inhibited
by several tumor-suppressor genes, including the subse-
quently discussed p16, p21, and p27. The amplification
and overexpression of this gene are independent progno-
sis factors in several tumors, including head and neck
SCC.57,58 Increased expression of cyclin D1 is associ-
ated with the presence of regional nodal metastases,
and advanced tumor stage. Therefore, it may be a useful
prognostic indicator, although some authors find these
data controversial.29,50,51
Cyclin A: Crucial for DNA synthesis in phase S and
G2!M progression, its overexpression has been corre-
lated with poorer prognosis in several human tumors.
High cyclin A indices correlate with advanced disease
stage, larger tumor volume, nodal metastases, and recur-
rence. It has been reported that patients with more than
15% cyclin Aepositive cells show a significantly
shorter survival when compared with those presenting
less than that value.59
Tumor-suppressor genes. p53: One of the most im-
portant genes influencing human carcinogenesis; pro-
tein p53 is involved in cell cycle control, apoptosis,
and the preservation of genetic stability. In carcinomas,
its expression is higher in those more undifferentiated,
correlating with a more burdensome prognosis; yet
some published works do not confirm these data, maybe
partly because the mutations precede the clinico-
pathologic changes.29,50,51,60-62 p53 gene mutations
may be better predictors of recurrence than the expres-
sion of the protein, and serum p53 levels may be more
efficient prognosticators than its tissue immunodetec-
tion.51 The impact of p53 in the prediction of tumor ra-
diosensitivity has been investigated with contradictory
results.29,50,63 p53 is an attractive target for gene ther-
apy; some experiments have been conducted using ade-
noviral vectors, and encouraging results have been
achieved.29
Rb: Its mutation or decrease of activity causes uncon-
trolled cellular proliferation. In OSCC the relation with
prognosis is not well established.29 However, Takes
et al.64 reported an association between loss of expres-
sion of gene Rb and higher probability of nodal metas-
tases in OSCC.p16: Halts cell cycle progression at G1. Deletions of
p16 seem to be crucial for the malignant progression,
and deletions of 9p21 influence survival, recurrence
rates, and the presence of nodal metastases. Allelic im-
balance at 9p21 predicts poorer prognosis.29,51
p21WAF1/CIP1: An inhibitor of cyclin-dependent ki-
nases, arresting cell cycle progression. Protein p21 is a
product of genes WAF1, CIP1, or SD11. The expression
of p21WAF1/CIP1 inversely correlates with parameter
T and clinical staging but not with parameter N, tumor
differentiation, or apoptotic variables. Patients with
tumors expressing higher values of p21WAF1/CIP1 have
longer disease-specific survival.65
p27kip1: Inhibitor of cyclin-dependent kinases, ham-
pering the transition G1!S; its low expression has
been correlated with worse prognosis in several human
tumors, including OSCC.66
p34cdc2: Cyclin-dependent kinase that regulates cel-
lular entry into mitosis; it is a cell proliferation index.
In p34cdc2-positive tongue SCC a significantly lower
survival has been found.67
Allelic imbalance (AI)/loss of heterozygosity (LOH).
In OSCC, patients showing AI at 1 or more loci in 3p24-
26, 3p13, or 9p21 may have mortality rates 25 times
higher.68 High fractional allelic loss correlates with
higher recurrence and less survival. Evidence exists
that AI at some specific pairs of loci is a better prognos-
ticator than the TNM staging system.68 In a study of
LOH at 2q, 3p, and 21q it was shown that allelic loss
in these regions is associated with the progression of
OSCC and correlates with worse prognosis, particularly
regarding 2q.69 The molecular study of these loci may
help select patients who should undergo more aggres-
sive therapies.
Ploidy. Abnormal DNA content has been associated
with advanced stage OSCC and other markers of poor
prognosis, such as lower degree of differentiation and
lymph node metastasis. It appears to be an independent
prognostic factor for relapse and death; it was found use-
ful also as a valuable differential diagnosis marker for
nondysplastic oral white patches or as predictor of oc-
cult nodal metastasis.70-72 However, debate has been
maintained over this issue owing to the reported intratu-
moral heterogeneity of DNA ploidy, with some authors
defending a homogeneous distribution of ploidy in the
tumor maintained even in the metastasis (although
ploidy has not been correlated with prognosis)73 and
others reporting heterogeneity and thus limited applica-
tion to predict prognosis.74 The study of DNA content
of cells in the tumor invasive front, considered important
to measure tumor aggressiveness (and therefore predict
outcome), suggested an influence on disease-specific
survival, especially if in conjunction with clinical
findings.75
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been used to assess cell proliferation. Their prognostic
value is still a matter of debate, because different
markers have been considered relevant to prognosis
in some papers whereas markers of proliferation failed
to correlate with the prognosis in other papers, a fact
attributed to heterogeneity of series, different ana-
tomic locations, or other differences in methodology.
Apparently, no single method will be able to predict
prognosis, but eventually a combination of static and
dynamic parameters of cell cycle (eg, immunohisto-
chemistry of Ki-67/MIB1 and silver staining of argyro-
philic nucleolar organizer regioneassociated proteins)
may prove to be a helpful and inexpensive prognostic
factor.29,76
Intercellular adhesion molecules. Intercellular adhe-
sion molecules are important for tumor development,
invasiveness, and appearance of metastases. Some al-
terations in expression and/or function are reported in
OSCC, and those more frequently associated with
OSCC prognosis concern E- and P-cadherins, catenins,
and CD44. Several papers correlate poorer prognosis
with primary tumor changes of CD44v9 phenotype,
with lower expression of CD44v3, and especially with
reduced expression of E-cadherin and P-cadherin.77-80
E-cadherin down-regulation was attributed to promoter
hypermethylation.81 Additionally, nodal metastases were
independently associated with decreased beta-catenin
expression.
Human papillomavirus (HPV). There is escalating
evidence of a causal association between HPV and
OSCC,82-93 with several studies showing that HPV is
associated with increased risk of oral cancer, inde-
pendently of exposure to tobacco and alcohol.84,86,88,89
This association is valid for high-risk HPV, which
comprises subtypes 16, 18, 33, and 35. HPV-16 may
be responsible for more than 80% of HPV-positive
OSCC.82,83,85-88,90,93 The virus can be detected in
tissues or cells using several methods, namely, bio-
chemical, immunologic, microscopic, and molecular.
Polymerase chain reaction is considered the most sensi-
tive assay.85,86
p53 remains the most commonly mutated gene in
many common human cancers, but in a high proportion
of cases lacking mutations its function is compromised
by other mechanisms.83,84,92 Regarding HPV, this may
occur via interaction of p53 with protein E6 encoded
by the oncogenic HPV types, mainly HPV-16 and
HPV-18, which results in increased ubiquitin-dependent
proteolysis of p53.82,83,92-94 The expression of wild-type
p53 in HPV-positive tumors contrasts with the higher
frequency of p53 mutation in HPV-negative cases, and
this fact seems to be associated with better prognosis
in patients with HPV-positive OSSC.82,83,94 Recentlypublished data on the prevalence of HPV infection in
OSCC points to rates between 15% and 30%, but this
might be an underestimation; it may ascend to more
than 50%.84,86,87,89,91 The disparity found in the pub-
lished data has been associated with variations in
collection of samples, the efficiency of the detection
procedure, and geographic parameters. It is not well
established how HPV infects the upper airway and
oral cavity, but epidemiologic evidence suggests sexual
transmission,82,93 because the prevalence of infection
increases after the onset of sexual activity, although
the presence of HPV in OSCC has not yet been robustly
linked to sexual practices such as oral sex.82
The presence of HPV DNA in a significant fraction of
OSCC raised the question of whether HPV tumor status
affects the outcome of oral cancer. To date, the findings
have been inconsistent, with some studies reporting
no survival differences84,87,94 and others clearly stating
a reduction in death risk among patients with HPV-
positive tumors when compared with those with HPV-
negative tumors.82,83,88,90-92 A large study conducted
by Gillison et al.82 has shown that patients with HPV-
positive tumors had a 60% reduction in risk of death
from cancer and significantly improved disease-specific
survival when compared patients with HPV-negative
tumors. Schwartz et al.90 also found a strong association
between the presence of HPV-16 DNA in OSCC and
prolonged survival. These findings support the theory
that HPV-positive OSSC may represent a distinct mo-
lecular, biologic, and clinical identity, supposedly
associated in causal terms with HPV infection and
possibly carrying better prognosis than HPV-negative
cases.82,83,90
Miscellaneous. Uridine phosphorylase (UPase) is an
enzyme that catalyzes the phosphorolysis of uridine to
uracil. Its expression and activity are increased in solid
tumors, including head and neck tumors. Positive UPase
marking correlates well with lymphatic metastases, but
not with tumor size or location, histologic differentia-
tion, or global survival.95 Protein S100A4 (involved in
the mobility of cancer cells) has been associated with
strong tumor invasiveness and higher probability of no-
dal metastasis.96 The expression of the glucose trans-
porter Glut-1 was studied in OSCC, as well as tumor
glucose metabolism. High levels of both parameters
correlated with a significantly shorter survival,97 which
is consistent with the notion that tumors with aggressive
biologic behavior present higher metabolic levels.
Lymphocytic infiltration surrounding invasive carcino-
mas is composed mainly of T lymphocytes, and repre-
sents a true immune response. The prognosis seems
better for marked infiltrations than for smaller
ones.27,29 A strong association between OSCC auto-
fluorescence (emitted by pigments of the porphyrin
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autofluorescence may be an indicator of tumor progres-
sion and, eventually, prognosis.98
Treatment-related factors
It is not our present intention whatsoever to evaluate
the efficacy of the several therapeutic modalities used
in OSCC. However, we should point out some issues
related to the treatment of OSCC with likely influence
on the outcome.
Cervical node dissection. Classically, the surgical
procedure employed in the presence of noticeable cer-
vical node metastases has been radical neck dissection
(for details regarding cervical node classification see
reference99). However, this procedure is a source of sig-
nificant postoperative morbidity, namely shoulder dys-
function, which may be minimized using a 2-stage
procedure. Furthermore, recently published work as-
serts that sparing 1 or both internal jugular veins is asso-
ciated with a reduction in mortality rates, not
endangering the prognosis.32 Selective neck dissection,
highly dependent on the primitive tumor location, ap-
parently achieves similar regional control and survival
rates as those attained with more extensive neck dissec-
tions.32 This approach may also serve staging purposes
and assist the selection of patients for adjuvant therapy.
Sentinel node detection, using lymphocyntigraphy or
dye injection, may be beneficial in the choice of the
type and extension of neck dissection, effectively de-
creasing the aggressiveness of surgical interventions.
The method is apparently not difficult to implement
and easily identifies the sentinel node.100,101 Ross
et al.100 have established the sensitivity of the procedure
as 94%, when using the lymphocyntigraphy, the dye,
and the full pathologic protocol.
Resection margin. A strong correlation has been
demonstrated between a resection margin free of disease
and higher survival rates, with longer time until recur-
rence of disease.11,31,35
DISCUSSION
Despite the attainments already achieved concerning
OSCC diagnosis and therapy, mortality and morbidity
rates are still exceedingly high, challenging the avail-
able methods of prognosis assessment and encouraging
the search for new and better markers, namely, molecu-
lar markers that relate comprehensively with known
alterations of tumor progression. The immense diversity
found in the field of clinical oncology must be consid-
ered from 2 main perspectives: the biologic distinctive-
ness of each patient and the biologic distinctiveness
of each malignancy. Currently, in practical terms, the
factors with greater consensual influence on disease
outcome include disease staging, extracapsular spread,tumor thickness, and resection margin free of disease.
In the future, better results in clinical oncology appear
to rely on improved understanding of tumor molecular
biology.
A vast number of molecular markers have been corre-
lated with OSCC outcome, illustrating the complex
events leading to carcinogenesis and cancer progres-
sion. Furthermore, some of the proposed markers are
frequently debated and sometimes results seem to con-
tradict each other. Several factors may explain this situ-
ation, such as the small number of individuals included
in each study or the heterogeneity of selected patients,
which frequently differ in various features, notably tu-
mor location. One other complexity is the possible intra-
tumoral heterogeneity of the marker, for which multiple
sampling of the tumor may be the key. Tumor invasive
front analysis is gaining relevance because it might bet-
ter reflect tumor-host interactions and consequently the
aggressiveness and prognosis.
A multitude of factors are involved in prognosis, and
probably no single marker can accurately predict the
final results. Tumor progression is a multifactorial and
multistep process; therefore multiple marker evaluation
may logically be required to estimate the final results.
Unfortunately, the widespread introduction of biologic
markers into daily clinical practice has been slow and
rather ineffective, hampering the completion of clinical
studies to assess their real usefulness and facilitate
their definitive implementation. In addition, the scatter-
ing of published data complicates the translation into
the clinical setting.
Global RNA expression analysis can be achieved by
DNA microarray technology, which has been used in
various cancers,102 including oral cancer,103,104 to obtain
gene expression profiles, associating them subsequently
with clinical features. The potential of this method is
vast, but one must not forget that cDNA microarray
assays can only analyze the transcriptome, whereas
biologic function is mediated mostly by proteins. RNA
levels do not always correlate with protein levels and
are not sensitive to post-translational modifications.
Recently, proteomic methods such as 2-D gel electro-
phoresis and high-throughput mass spectrometry have
been used to establish salivary proteome, and reliable in-
formation can be obtained through them. Multiple bio-
marker analysis can establish patterns which may be
associated with the outcome.105,106 However, complex
patterns may be difficult to discern by the human eye
and mind, and bioinformatics algorithms will probably
be useful. Proteomic analysis of whole body fluid protein
components has been developed for the monitoring of
health status and for early disease diagnosis and charac-
terization. In addition, salivary biomarkers, relying on a
supposed link between salivary proteins and systemic
OOOOE
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ple markers present in saliva, a noninvasive and readily
available method, may become in the future a powerful
bedside technique.105-107
Conceivably, an upcoming all-inclusive molecular
and clinical staging system will allow a more accurate
selection of patients that should undergo more aggressive,
specific, or individualized cancer therapy. We believe
that further knowledge and subsequent application of
the methods exposed above will definitely increase prog-
nostic and therapeutic success, effectively decreasing
morbidity and mortality rates associated with OSCC.
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